Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Georg-Nikolaus Franke, MD, Jacqueline Maier, PhD, Kathrin Wildenberger, Christine Günther, Michael Cross, PhD, Thomas Ernst, MD, Christian Fabisch, PhD, Dietger Niederwieser, MD, Andreas Hochhaus, MD, Thoralf Lange, MD

Blood (2017) 130 (Supplement 1): 252.

https://doi.org/10.1182/blood.V130.Suppl_1.252.252

Published: 2017

Journal Articles

Prevalence and Dynamics of Clonal Hematopoiesis Caused By Leukemia Associated Mutations in Elderly Individuals without Hematologic Disorders

Thomas Ernst, MD, Jenny Rinke, Danica Midic, Violetta Müller, Anja Waldau, Alexander Kaiser, MD, Bernd Gruhn, Jürgen Landschulze, MD, Frank Pester, MD, Andreas Hochhaus, MD

Blood (2017) 130 (Supplement 1): 1141.

https://doi.org/10.1182/blood.V130.Suppl_1.1141.1141

Published: 2017

Journal Articles

CTLA-4 Polymorphisms: Influence on Transplant-Related Mortality and Survival in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Bernd Gruhn, MD, Susan Wittig, Thomas Ernst, MD, Judith Hammrich

Blood (2016) 128 (22): 67.

https://doi.org/10.1182/blood.V128.22.67.67

Published: 2016

Journal Articles

Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia

Lai N Chan, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Gang Xiao, PhD, Zhengshan Chen, MD PhD, Thomas Ernst, MD, Andreas Hochhaus, MD, Markus Müschen, MD PhD

Blood (2016) 128 (22): 2771.

https://doi.org/10.1182/blood.V128.22.2771.2771

Published: 2016

Journal Articles

Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia

Thomas Ernst, MD, Jenny Rinke, Melinda Busch, Jana Ernst, MD, Ellen Obstfelder, Mathias Schmidt, MD, Vivien Schäfer, Anja Waldau, Nils Winkelmann, MD, Bernd Gruhn, MD, Andreas Hochhaus, MD

Blood (2016) 128 (22): 1221.

https://doi.org/10.1182/blood.V128.22.1221.1221

Published: 2016

Journal Articles

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

Thomas Ernst, MD, Vivien Schäfer, Helen E White, PhD, Susanne Saussele, MD, Thoralf Lange, MD, Gareth Gerrard, PhD, Nicholas CP Cross, PhD, Andreas Hochhaus, MD

Blood (2016) 128 (22): 1918.

https://doi.org/10.1182/blood.V128.22.1918.1918

Published: 2016

Journal Articles

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

Sebastian Birndt, Thomas Schenk, MD, Frank M. Brunkhorst, MD, Georg Maschmeyer, MD, Frank Rothmann, MD, Thomas Weber, MD, Markus Müller, MD, Jens P. Panse, MD, Roland Schroers, MD, Jan Braess, MD, Norbert Frickhofen, MD, Gritta Janka, MD PhD, Kai Lehmberg, MD, Andreas Hochhaus, MD, Thomas Ernst, MD, Paul La Rosée, MD

Blood (2016) 128 (22): 2523.

https://doi.org/10.1182/blood.V128.22.2523.2523

Published: 2016

Journal Articles

B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling

Blood (2015) 126 (23): 1255.

https://doi.org/10.1182/blood.V126.23.1255.1255

Published: 2015

Journal Articles

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Blood (2015) 126 (23): 1569.

https://doi.org/10.1182/blood.V126.23.1569.1569

Published: 2015

Journal Articles

Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia

Lai N Chan, PhD, Daniel Braas, Christian Hurtz, PhD, Seyedmehdi Shojaee, PhD, Behzad Kharabi Masouleh, MD, Huimin Geng, PhD, Thomas Ernst, MD, Andreas Hochhaus, MD, Thomas Graeber, PhD, Markus Muschen, MDPhD

Blood (2014) 124 (21): 783.

https://doi.org/10.1182/blood.V124.21.783.783

Published: 2014

Journal Articles

A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV

Blood (2014) 124 (21): 3138.

https://doi.org/10.1182/blood.V124.21.3138.3138

Published: 2014

Journal Articles

Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status

Thomas Ernst, MD, Mathias Schmidt, Jenny Rinke, Vivien Schäfer, Anja Waldau, Ellen Obstfelder, Nils Winkelmann, MD, Janine Ziermann, PhD, Susanne Schnittger, PhD, Torsten Haferlach, MD PhD, Claudia Haferlach, MD, Andreas Hochhaus, MD

Blood (2014) 124 (21): 4513.

https://doi.org/10.1182/blood.V124.21.4513.4513

Published: 2014

Journal Articles

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

Juliana Schwaab, MD, Philipp Erben, MD, Hans-Peter Horny, MD, Martina Teichmann, MD, Georgia Metzgeroth, MD, Thomas Ernst, MD, Karl Sotlar, MD, Martin C Mueller, MD, Alexander Marx, MD, Karin Hartmann, MD, Andreas Hochhaus, MD, Nicholas C.P. Cross, PhD, Wolf Karsten Hofmann, MD, PhD, Andreas Reiter, MD

Blood (2012) 120 (21): 2859.

https://doi.org/10.1182/blood.V120.21.2859.2859

Published: 2012

Journal Articles

Frequency and Clinical Presentation of Polycomb Repressive Complex 2 (PRC2) Component Mutations in Childhood Acute Lymphoblastic Leukemia

Thomas Ernst, MD, Vivien Schäfer, Jenny Rinke, Anja Waldau, Susan Wittig, Jana Ernst, MD, Ralf Häfer, PhD, James F Beck, MD, Andreas Hochhaus, MD, Bernd Gruhn, MD

Blood (2012) 120 (21): 1474.

https://doi.org/10.1182/blood.V120.21.1474.1474

Published: 2012

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Nicholas C.P. Cross, PhD, FRCPath, Joannah Score, PhD, Claire Hidalgo-Curtis, PhD, Amy V Jones, PhD, Nils Winkelmann, MD, Alison Skinner, BSc, Daniel Ward, MSc, Katerina Zoi, MD, PhD, Thomas Ernst, MD, Frank Stegelmann, MD, Konstanze Dohner, MD, PhD, Andrew J Chase, PhD

Blood (2011) 118 (21): 617.

https://doi.org/10.1182/blood.V118.21.617.617

Published: 2011

Journal Articles

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Paola Guglielmelli, MD, PhD, Flavia Biamonte, BiSc, Johannah Score, Claire Hidalgo-Curtis, PhD, Francisco Cervantes, MD, PhD, Margherita Maffioli, MD, Tiziana Fanelli, BiSci, Thomas Ernst, MD, Nils Winkelman, MD, Amy V Jones, PhD, Katerina Zoi, MD, PhD, Andreas Reiter, MD, Andrew Duncombe, MD, Laura Villani, Biol Sci, Chiara Paoli, BiSci, Alberto Bosi, MD, Giovanni Barosi, MD, Nicholas C.P. Cross, PhD, Alessandro M. Vannucchi, MD

Blood (2011) 118 (21): 2811.

https://doi.org/10.1182/blood.V118.21.2811.2811

Published: 2011

Journal Articles

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Thoralf Lange, MD, Thomas Ernst, MD, Markus Pfirrmann, PhD, Jacqueline Maier, PhD, Martin C. Müller, MD, Franz Gruber, MD, Dietger Niederwieser, MD, Andreas Hochhaus, MD

Blood (2011) 118 (21): 1679.

https://doi.org/10.1182/blood.V118.21.1679.1679

Published: 2011

NARROW

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Incidence of Low Level Mutations in Newly Diagnosed CML Patients: A Substudy of the German Tiger Trial

Prevalence and Dynamics of Clonal Hematopoiesis Caused By Leukemia Associated Mutations in Elderly Individuals without Hematologic Disorders

CTLA-4 Polymorphisms: Influence on Transplant-Related Mortality and Survival in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Identification of the Energy Stress Sensor AMPK As Therapeutic Target in Acute Lymphoblastic Leukemia

Prevalence and Dynamics of BCR-ABL Independent Gene Mutations in Patients with Chronic Myeloid Leukemia

Assessment of Molecular Response in CML Patients with Atypical BCR-ABL Tanscripts. Recommendations By the EUTOS Collaboration

Hemophagocytic Lymphohistiocytosis in Adults (aHLH): Results from the German HLH Registry

B-Lymphoid Transcription Factors Restrict Glycolytic Energy Supply for Oncogenic Signaling

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia

Lineage-Specific Metabolic Reprogramming Reveals LKB1 as Therapeutic Target in Acute Lymphoblastic Leukemia

A Two-Fold Rise of BCR-ABL Transcript Levels Advises BCR-ABL Mutation Analysis in Imatinib-Treated Chronic Myeloid Leukemia (CML) - an Analysis of the Randomized CML-Study IV

Molecularly Defined Clonal Evolution in Patients with Chronic Myeloid Leukemia Independent of the BCR-ABL Status

The KIT D816V Allele Burden in Systemic Mastocytosis Is Strongly Associated with Disease Subtype.

Frequency and Clinical Presentation of Polycomb Repressive Complex 2 (PRC2) Component Mutations in Childhood Acute Lymphoblastic Leukemia

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Prognostic Impact of EZH2 and ASXL1 Mutation in Myelofibrosis

Absolute Quantification of Mutant T315I BCR-ABL Transcripts At 6 Months Identifies Imatinib Resistant CML Patients with a Low Probability to Achieve MMR After 12 Months on Second Line Tyrosine Kinase Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only